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Abstract
Background: The cause of isolated gonadotropin-independent precocious puberty (PP) with an ovarian cyst is unknown in
the majority of cases. Here, we describe 11 new cases of peripheral PP and, based on phenotypes observed in mouse
models, we tested the hypothesis that mutations in the GNAS1, NR5A1, LHCGR, FSHR, NR5A1, StAR, DMRT4 and NOBOX may
be associated with this phenotype.
Methodology/Principal Findings: 11 girls with gonadotropin-independent PP were included in this study. Three girls were
seen for a history of prenatal ovarian cyst, 6 girls for breast development, and 2 girls for vaginal bleeding. With one
exception, all girls were seen before 8 years of age. In 8 cases, an ovarian cyst was detected, and in one case, suspected. One
other case has polycystic ovaries, and the remaining case was referred for vaginal bleeding. Four patients had a familial
history of ovarian anomalies and/or infertility. Mutations in the coding sequences of the candidate genes GNAS1, NR5A1,
LHCGR, FSHR, NR5A1, StAR, DMRT4 and NOBOX were not observed.
Conclusions/Significance: Ovarian PP shows markedly different clinical features from central PP. Our data suggest that
mutations in the GNAS1, NR5A1, LHCGR, FSHR StAR, DMRT4 and NOBOX genes are not responsible for ovarian PP. Further
research, including the identification of familial cases, is needed to understand the etiology of ovarian PP.
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Introduction
Precocious puberty (PP) in girls is defined by the development of
sexual characters (development of breasts, pubic and menstrual
bleeding) and increased growth rate before 8 years-of-age [1].
There are two major categories of precocious puberty: true or
central PP and pseudo or peripheral PP. True PP is associated
with the premature activation of the hypothalamic-pituitary-
gonadal axis [1,2]. Peripheral PP is characterized by the
development of secondary sexual characteristics mainly due to
estradiol secretion originating from either adrenals or from
ovaries. True and peripheral isosexual PP can be distinguished
by measuring basal, and gonadotropin releasing hormone
(GnRH)-stimulated luteinising hormone (LH) and follicle stimu-
lating hormone (FSH) peaks concentrations. These concentrations
increase in true PP [3] while they are low and do not increase in
peripheral PP.
Peripheral PP of ovarian origin is a rare condition compared to
true PP. It may be associated with an ovarian cyst and it is often
transient and frequently recurrent. It may be due to granulosa cell
tumor [4] or may be one symptom of the McCune-Albright
Syndrome (MAS). MAS is a sporadic disease, characterized by the
triad of polyostotic fibrous dysplasia, cafe ´-au-lait skin pigmenta-
tion, and endocrine dysfunction, with individuals exhibiting
peripheral PP. It is due to post-zygotic-activating recurrent
mutations in the guanine-nucleotide-binding protein (G protein)
a-subunit (Gsa) [5]. The phenotype is variable and some patients
carrying the mutation show only PP [5–9].
A number of other gene mutations could be responsible for
peripheral PP. Women carrying homozygous inactivating LHCGR
mutations have hypergonadotropic hypogonadism with primary
amenorrhea or oligoamenorrhea, cystic ovaries, and infertility
[10]. Mutations in the FSHR gene are associated with ovarian
hyperstimulation syndrome that includes the presence of multiple
serous and hemorrhagic follicular cysts [11]. 46,XX girls with
mutations in the gene encoding Steroidogenic Acute Regulatory
(StAR) protein spontaneously undergo puberty but ultimately
develop ovarian cysts by an unknown mechanism [12]. A number
of mouse knockouts also exhibit ovarian anomalies that may a
genetic model for peripheral PP. The orphan nuclear receptor
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at multiple levels of the reproductive axis and controls the gonadal
expression of multiple genes that are essential for reproduction
[13]. Mice carrying a granulosa-specific Nr5a1 knockout are sterile
with ovaries that contain cysts [14]. Genes containing an
evolutionary conserved DM domain are involved in various
aspects of sexual development [15]. One member of the family,
DMRT4 is widely expressed during embryonic and postnatal
development [15]. Mice lacking Dmrt4 develop essentially
normally, undergo full sexual differentiation in both sexes, and
are fertile but females develop ovarian cysts [16]. Mice lacking
Nobox, an oocyte-specific homeobox gene that is expressed in germ
cell cysts and in primordial and growing oocytes, exhibit ovarian
cysts at birth [17].
We analysed an exceptional series of 11 unrelated girls who
presented with a prepubertal isolated ovarian cyst. In 4 cases there
was a familial history of ovarian anomalies and/or infertility. We
tested the hypothesis that mutations in the GNAS1, LHCGR, FSHR,
StAR, NR5A1, DMRT4 and NOBOX could contribute to the
phenotype.
Materials and Methods
Ethics statement
All patients provided informed consent prior to participation in
this study. The study was approved by local ethics committees. All
clinical investigations were conducted according to the principals
expressed in the Declaration of Helsinki.
Patients
Written informed consent for the evaluation and molecular
analyses was obtained from the parents. This study consisted of 11
girls referred to one of us (R. Brauner) with prepubertal isolated
ovarian cyst. None of them had the other characteristic features of
the neither MAS nor hypothalamic-pituitary lesion. Complete
skeletal radiographic examination, and plasma concentrations of
thyroid stimulating hormone, thyroxine, prolactin, b human
chorionic gonadotropins and a-fetoprotein, measured at various
intervals in each girl, were normal, as was the hypothalamic-
pituitary area evaluated by magnetic resonance imaging.
The initial evaluation included determinations of height, growth
rate [18], weight, pubertal stage [19], bone age [20], pelvic
ultrasound examination, and measurement of plasma inhibin B
(n=4), anti-Mu ¨llerian hormone (AMH, n=3), dehydroepiandros-
terone sulfate, testosterone and delta 4 androstenedione concen-
trations. The hypothalamic-pituitary-ovarian axis was evaluated
by measuring basal and GnRH (100 mg/m
2)-stimulated LH and
FSH peaks and the plasma estradiol concentrations. The biological
evaluations were not complete in one girl with ovarian cyst
diagnosed prenatally (Table 1). The values considered to be
prepubertal were: uterus length of ,35 mm [21], LH/FSH peaks
ratio after GnRH test ,0.66 [3], and plasma estradiol
concentrations ,15 pg/ml (55 pmol/l).
Molecular analyses
Genomic DNA was extracted from peripheral blood leucocytes
and ovarian cyst tissue (case 9) by standard methods. The exons 8
and 9 of the GNAS1 gene were directly sequenced following PCR
amplification essentially as described elsewhere with minor
modifications [5]. Sequencing the gene coding for NR5A1, LHCGR
and FSHR was performed as described elsewhere [13,22,23]. The
primers and PCR conditions for amplification of the StAR,
DMRT4 and NOBOX are provided in supplementary material
(Table S1). The recurring mutations at codons 201 and 227 of the
GNAS1 gene were screened by denaturating gradient gel
electrophoresis (DGGE) analysis using chemical clamps instead
of guanine-cytosine tails [5]. Computer algorithms were used to
predict the fragment melting behavior and to determine the
appropriate denaturant concentration range. An aliquot (1/10) of
the amplified product was clamped by ultraviolet irradiation
(365 nm) and loaded on a 6% polyacrylamide gel with a linearly
parallel gradient of 30–60% denaturant (exon 7) or 50–80%
denaturant (exon 9) and electrophoresed at 160 V (80 mA) for
7 hours. The amplified PCR products were purified and
sequenced using the Dye terminator cycle sequencing kit (Perkin
Elmer/Applied Biosystems, USA) and an ABI 377 machine.
Results
Three patients were seen for history of prenatal ovarian cyst, 6
for breast development and 2 for vaginal bleeding all before 8
years of age (except case 11 aged 9.2 years, Table 1). All, except
case 5, had a large unilateral ovarian cyst (17–60 mm) or
polycystic ovaries (case 9) or a concomitant blood effusion in the
Douglas cul-de-sac (case 11). In five patients, the plasma
concentrations of LH and FSH were low and did not increase
after GnRH stimulation. In five other cases plasma concentrations
and response were prepubertal. They were not evaluated in case 3.
Familial history and genetic analysis
Four patients had a familial history of ovarian anomalies and/or
sterility (Figure 1). These data suggest a strong genetic contribution
to the phenotype in each case, but no mutations in the GNAS1,
LHCGR, FSHR, StAR, NR5A1, DMRT4 and NOBOX were found,
including DNA extracted from the ovarian cyst tissue in case 9.
Cases descriptions
Case 1 was referred for breast development at 1.3 years. A left
ovarian cyst of 37 mm was diagnosed at ultrasonography
performed at a gestational age of 33 weeks. At birth, it enlarged
to 48 mm and was surgically removed at the age of 1 month. At
1.3 years, plasma basal LH and FSH concentrations and their
response to GnRH test and estradiol were prepubertal. Ultraso-
nography showed normal ovaries. She has not been investigated
since this time.
Case 2 was referred for a prenatal right ovarian cyst of 24 mm
seen at ultrasonography performed at a gestational age of 33
weeks. It enlarged to 48 mm at 35 weeks and then diminished to
32 mm at birth. After birth, it progressively disappeared. Her
mother also had a history of ovarian cyst (Figure 1). The patient
was assessed at 1.7 years with no clinical evidence for PP. Plasma
basal LH and FSH concentrations and their response to GnRH
test were prepubertal. Plasma concentrations were prepubertal for
estradiol and 22 pg/ml for inhibin B. Ultrasonography showed
normal ovaries with small follicles. No medical problem has
occurred in the last year since this assessment.
Case 3 was referred at 9.7 years for history of prenatal ovarian
left cyst (37 mm) leading to ovariectomy for a necrotic ovary on
the first day of life. The right ovary was initially polycystic and
enlarged (30 mm) and then returned to normal. She has no
pubertal development, and the clinical evaluation was normal. No
GnRH test was performed and the current follow-up consists of an
annual ultrasonography and clinical assessment.
Case 4 was referred for two episodes of breast development
associated with vaginal bleeding at the first month of life and at 2
years. Plasma basal LH and FSH concentrations and their
response to GnRH test were prepubertal. Plasma estradiol
concentration was not measured, but the vaginal smear showed
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androsterone sulfate was 110 ng/ml and progesterone was
,0.05 ng/ml. Ultrasonography showed normal ovaries. Seven
episodes of breast development occurred until the age of 5.8 years.
Three of these were accompanied by vaginal bleeding and one was
accompanied by abdominal pain, During these episodes, the
ultrasonography showed a right ovarian cyst of 20 mm at 5 years
and of 11 mm at 5.8 years. Since the vaginal bleeding was
spontaneously regressive and the bone age was not advanced, she
was not treated and no other bleeding episodes occurred.
Menarche occurred at 13 years followed by regular menstruations.
Adult height is 166 cm.
Case 5 had neonatal breast development and was referred for
vaginal bleeding at 0.4 years. Plasma basal LH and FSH
concentrations and their response to GnRH test and estradiol
were prepubertal. Ultrasonography showed a uterine vacuity line,
while the ovaries were not seen. Other plasma concentrations were
dehydroepiandrosterone sulfate 130 ng/ml and progesterone
,0.05 ng/ml. Five episodes of vaginal bleeding occurred until
the age of 2.8 years. Gynecologic examination and complete
haemostasis tests were normal. At 9.5 years, another episode of
vaginal bleeding occurred. Gonadotropins response to the GnRH
test was again prepubertal (peaks LH 3.6 and FSH 14.3 IU/l, with
plasma concentrations of 37 pmol/l for estradiol, 6.5 pmol/l for
AMH and ,10 pg/ml for inhibin B). Ultrasonography showed
round ovaries without a cyst. Bone age was 10 years. She was then
lost for follow-up for 10 years. During this period she reported
irregular menstrual cycles. Adult height is 173 cm. At 21 years, she
had regular menstrual cycles due to estro-progestative contracep-
tion. Plasma basal concentrations measured after stopping this
were LH 9.4 IU/l, FSH 9.9 IU/l, testosterone 0.24 ng/ml and
delta-4-androstenedione 1.2 ng/ml. Ultrasonography showed
normal ovaries. As four paternal aunts were infertile (Figure 1),
her chromosome complement was analyzed and was 46,XX.
Case 6 was referred for breast development and vaginal
bleeding at 2.2 years. Previous vaginal bleeding had occurred at
the age of 1.5 years, but it did not lead to a medical evaluation.
Plasma basal LH and FSH concentrations were low and they did
not increase after GnRH stimulation test, while estradiol was
prepubertal with inhibin B,10 pg/ml. Ultrasonography showed a
left ovarian cyst and a normal right ovary. There was no evidence
for a tumoral mass neither by pelvic magnetic resonance imaging
nor by blood tests.
Case 7 was referred for breast development at 3.3 years, with
areolas pigmentation, followed one month later by an episode of
vaginal bleeding. She was one of two non-identical twin girls,
born at 28 weeks of gestation, weighting 0.740 kg. She had
prolonged ventilation. Plasma basal LH and FSH concentra-
tions were low and did not increase after GnRH stimulation.
Ultrasonography showed a left ovarian cyst, a normal right
ovary and a pubertal uterus length. Because of the large
dimension of the cyst, treatment by oral cyproterone acetate was
initiated at the dose of 25 mg (1.8 mg/kg)/day. Estrogenization
signs disappeared in 5 months. The ovarian cyst decreased,
measuring 28 mm at 4.7 years and then disappeared. Treatment
i sb e i n gc o n t i n u e d ,a tad e c r e a s e dd o s eo f1 2 . 2 5m g( 0 . 8m g /
kg)/day since the age of 4.3 years. Ultrasonography did not
show ovarian cyst at 6.1 years.
Case 8 was referred for breast and pubic hair development at
5.6 years. For more than one year, she had intermittent clear
vaginal discharge. Plasma basal LH and FSH concentrations
were low and did not increase after GnRH stimulation test,
Table 1. Characteristics of 11 girls with prepubertal isolated ovarian cyst.
First symptom First evaluation
GnRH
stimulation
test
Pelvic
ultrasono-
graphy
LH FSH Ovarian cyst
Uterus
length
Case
Age
years Type
Age
years
Bone
age
years
Growth
rate zs
Tanner
stage basal-peak, IU/l
Estradiol
pmol/l mm mm Evolution
Last
evaluation
age years
1 Prenatal Ovarian
cyst
1.3 ND 1 B2 P1 01–07 2.7–34.5 ,37 Normal ovaries 25 L cystectomy 1.3
2 Prenatal Ovarian
cyst
1.7 ND 1 B1 P1 0.9–2.2 1.8–23.5 ,37 Normal ovaries 27 Regression 1.7
3 Prenatal Ovarian
cyst
9.7 ND 1 B1 P1 ND ND ND Normal R ovary 20 L ovariectomy 9.7
4 0.1 B2 M 2.1 2.8 0 B3 P1 0.5–4.3 1.6–14 ND Normal ovaries* ND Recurrent M 23.5
5 0.1 B2 M 0.8 0.9 1 B2 P1 1–7.2 7–28 ,37 Ovaries not seen 30 Recurrent M 21
6 1.5 M 2.2 3.5 2 B2 P1 ,0.4–0.6 ,0.4–0.8 9 L 17 36 Recurrent M 2.2
7 3.3 B2 M 3.3 ND 0 B3 P1 ,0.1–,0.1 ,0.1–1.1 66 L 50 57 CA treatment 6.4
8 5.6 B2 P2 5.7 4.5 1 B3 P2 ,0.4–,0.4 ,0.4–,0.4 918 L 60 53 CA treatment 13.5
9 5.8 B2 6.6 7.8 1.5 B3 P1 ,0.2–0.74 ,0.2–0.5 ,37 Polycystic ovaries 34 Ovariopexy 9.5
10 6.6 B2 6.7 6.5 0 B3 P1 ,0.4–,0.4 ,0.4–,0.4 576 L 41 58 CA treatment 8.4
11 9.2 M 9.2 ND 1 B1 P1 ,0.2–1.2 0.53–5 ,37 Normal ovaries** 25 Recurrent M 11.3
*Ovarian cyst of 20 mm at 5 years; **blood effusion in the Douglas cul-de-sac.
B breast, P pubic hair, M vaginal bleeding, L: left; R right, ND, not determined, CA cyproterone acetate.
doi:10.1371/journal.pone.0011282.t001
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ovarian cyst, normal right ovary with small follicles, and a
pubertal uterus length. Because of the large dimension of the
cyst, treatment by oral cyproterone acetate was initiated at the
dose of 75 mg (3 mg/kg)/day. The ovarian cyst disappeared
after 7 months. Discontinuation of treatment was followed by
resurgence of clear vaginal discharge less than 2 months later.
Treatment was resumed at the dose of 25 mg/day. At 7.5 years,
a 19x10mm left ovarian cyst was seen at ultrasonography, with a
uterus length of 40mm. There was no clinical sign of
estrogenisation. The treatment dosage was increased to 50 mg
(0.9 mg/kg)/day until 10.5 years. Plasma estradiol concentra-
tion was ,37 pmol/l at 9.8 years. Menarche occurred at 11.5
years followed by regular menstruations.
Case 9 was referred for breast development at 5.8 years, with
a familial history of ovarian anomalies (Figure 1). Plasma basal
concentrations of LH and FSH were low and and did not
increase after GnRH stimulation test, while the estradiol level
was ,37 pmol/l. Ultrasonography showed polycystic ovaries.
During the initial follow-up, ultrasonography showed no
modification. She was not treated because breast development
and bone age did not progress. Plasma concentrations were
testosterone ,0.05 ng/ml and delta-4-androstenedione
0.74 ng/ml at 8.8 years. At 9.3 years, her Tanner stage was
B4 P1, and ovaries size was increased, with a larger diameter of
60 and 70 mm and many cysts, measuring 8 to 12 mm. The
plasma concentrations were 381 pmol/l for AMH and 94 pg/ml
for inhibin B. At 9.4 years, ovariopexy and multiple ovarian
biopsies were performed: macroscopically, both ovary diameters
were more than 100 mm, and there were multiple cortical cysts,
with no sign of malignancy. Plasma estradiol concentration in
the cyst fluid was 1945 pmol/l.
Case 10 was referred for breast development with areolas
pigmentation and a clear vaginal discharge at 6.6 years. There is
a familial history of ovarian anomalies (Figure 1). Plasma basal
LH and FSH concentrations were low and did not increase after
GnRH stimulation test, whilst plasma estradiol concentration
was high. Ultrasonography showed a left ovarian cyst, a normal
right ovary with small follicles and a pubertal uterus length.
B e c a u s eo ft h el a r g ed i m e n s i o no ft h ec y s t ,t r e a t m e n tb yo r a l
cyproterone acetate was initiated at the dose of 50 mg (1.8 mg/
kg)/day. Three months later, breast development decreased, the
ovarian cyst disappeared, the plasma concentration of estradiol
decreased to ,37 pmol/l, while AMH was 25 pmol/l and
inhibin B ,10 pg/ml. The dose was when decreased to
12.25 mg (0.5 mg/kg)/day. At 8.4 years, she remained under
Figure 1. Pedigrees of 4 cases with familial history of ovarian anomalies. In case 2, the mother had an orange-sized ovarian cyst that was
removed surgically in emergency at the age of 10 years. In case 5, four paternal aunts had vaginal bleeding and all were reported as infertile; in
addition both the mother and maternal grandmother also reported menometrorragias. Hysterectomy was performed in the mother at 42 years
because of a uterus fibroma diagnosed at 30 years. In case 9, the mother had an ovarian dermoid cyst at 25 years, leading to an ovariectomy; her
mother’s aunt was infertile, due to an undetermined ovarian trouble, after a menarche at the age of 10 years; her grand-mother’s cousin underwent
ovariectomy for an ovarian cyst. In case 10, the mother had ovarian cysts although there was no evidence of PP. Squares represent male family
members, whilst circles represent female family members. The proband in each case is indicated by an arrow. Solid symbols indicate individuals with
ovarian cysts. Shaded symbols indicate individuals with infertility and/or ovarian anomalies.
doi:10.1371/journal.pone.0011282.g001
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ultrasonography was normal.
Case 11 was referred for vaginal bleeding at 9.2 years. There
was no breast or pubic hair development. Plasma basal LH and
FSH concentrations and their response to GnRH test and plasma
estradiol concentrations were prepubertal. Ultrasonography
showed normal ovaries. The following two years were character-
ized by periodic vaginal bleeding, once a month and then twice a
month in the last year. Iterative pelvic ultrasonographies did not
reveal any ovarian cyst but indirect evidence for it was seen by a
blood effusion in the Douglas cul-de-sac.
Discussion
Here, we have described the clinical-biological presentation and
genetic analyses of 11 rare cases of precocious puberty with
ovarian cysts. ‘‘Idiopathic’’ ovarian PP shows markedly different
features from central PP. It raises the questions of differential
diagnosis from ovarian tumor, the risk of developing ovarian
torsion and influencing bone age progression induced by the
estrogen secretion that can lead to a short adult height.
Clinical and biological presentation
The presentation of the 8 postnatally diagnosed cases differs
from the typical presentation of central PP. Signs of estrogenisa-
tion were intense, developed quickly and they were associated
with vaginal bleeding in 5 of the cases. In 5 of the 8 cases the
p l a s m ab a s a lL Ha n dF S Hc o n c e n t r a t i o n sw e r el o wa n dd i dn o t
increase after GnRH stimulation. Their evolution was also
unusual with spontaneous regression in 4 cases with recurrent
episodes. In our experience, in patients with central PP, vaginal
bleeding occurs associated with hypothalamic hamartoma or
suprasellar arachnoid cysts but it does not occur in idiopathic
forms [2,24]. These central PP cases are associated with
pubertal gonadotropin response to the GnRH test [25]. In the
patients of the present study, a hypothalamic-pituitary lesion
was excluded by magnetic resonance imaging and none had
pubertal response to GnRH stimulation test. The cysts in the
patients here were all greater than 17 mm diameter. An isolated
o v a r i a nc y s to fm o r et h a n8 – 1 0 m md i a m e t e rs u g g e s t sa
peripheral origin of the PP, while in central puberty both
ovaries are characteristically enlarged and multifollicular
[26,27]. This would explain the rapid estrogenisation signs
followed by regression. The short time of the secretion of
estrogens, even if repeated, probably explains the absence of a
significant bone age progression leading to a normal adult
height reached by the two older patients.
Diagnosis and prognosis
Peripheral PP may be the first symptom of an ovarian tumor,
including granulosa cell tumor, which is present in 1% of all
peripheral PP [28]. In a previous study of prepubertal girls with
ovarian granulosa cell tumor [4], 17/29 presented with PP.
However, two girls were misdiagnosed with ovarian cyst, since this
tumor is frequently heterogeneous and can have a cystic
component [29]. This is important, because a delayed diagnosis
is known to worsen the overall prognosis [29]. In our series, a
tumor was suspected in case 9 but surgical biopsies eliminated this
diagnosis. In the other patients, the disappearance of the ovarian
cysts suggests tumors are absent. Plasma AMH and inhibin B
concentrations were measured in the 4 more recent cases because
granulosa cell tumors may secrete these hormones [30] and AMH
is increased in prepubertal daughters of women with polycystic
ovary syndrome [31]. In 4 cases, the symptoms regressed
spontaneously. In three cases, the treatment with cyproterone
acetate was associated with regression of clinical-biological-
radiological abnormalities. The risks of ovarian torsion due to
the volume of the ovarian cyst and of recurrence of estrogenic
signs required a careful follow-up.
Molecular analyses
The genetic basis of ovarian precocious puberty is unknown.
The presentation of the 11 cases may form part of the clinical
spectrum of the MAS and, therefore they may carry activating
mutations in the GNAS1 gene. A mutation screen in all cases failed
to detect a mutation. However, in 10/11 cases lymphocyte DNA
was analyzed and a post-zygotic somatic mutation confined to the
ovaries cannot be excluded. A previous study found a GNAS1
mutation in the cystic fluid of a girl with isolated peripheral PP
who had no other clinical presentation of MAS during a 40
months follow up [8]. However, bone anomalies were not
excluded and the patient did not respond to cyproterone acetate
treatment, which suggests a different clinical presentation to the
cases reported here. In a study of 39 girls presenting isolated
peripheral PP [5], GNAS1 mutations were observed in 13 cases
(33%). Five of these patients did not show either skin or bone
lesions during their follow up, or were lost to follow up. In a
separate study somatic MAS features also developed in 3 patients
two years (15–40 months) after vaginal bleeding [32]. Here,
GNAS1 mutations were not found in ovarian cystic tissue of case 9.
In the remaining cases of our study the mean follow up period is
10.9 years, yet none of the patients developed characteristic MAS
anomalies. A familial history of ovarian anomalies was reported in
four of the cases reported here also arguing against the
involvement of the GNAS1 gene.
W es c r e e n e das e r i e so fc a n d i d a t eg e n e sf o rm u t a t i o n st h a t
could be associated with the development of ovarian cysts.
Mutations of the LHCGR and FSHR genes may result in the
development of ovarian cysts or hyperfunction [10,11], however
in this study we did not identify mutations in either of these
genes. Based on the mouse knockout phenotypes, mutations
involving the NOBOX, DMRT4, NR5A1 or StAR genes could be
associated with cyst formation, however we did not detect
mutations in the coding sequences of these genes in any of the
cases described here. Although we did not detect mutations in
these genes it is probable that a genetic factor is contributing to
the phenotype since in several cases there was a family history of
ovarian anomalies.
Supporting Information
Table S1 List of primer sequences and PCR cycling conditions
used for NOBOX, DMRT4 and STAR genes in the study. In
each amplication, 37 cycles were performed using 10ng of
genomic DNA.
Found at: doi:10.1371/journal.pone.0011282.s001 (0.07 MB
DOC)
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